JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients

被引：10

作者：

Florensa, L. ^{[1
]}

Bellosillo, B.

Besses, C.

Puigdecanet, E.

Espinet, B.

Perez-Vila, E.

Longaron, R.

Vila, R. M.

Sole, F.

Serrano, S.

机构：

[1] Hosp del Mar, IMAS, Dept Patol, Lab Citol Hematol, Barcelona, Spain

[2] Parc Rec Biomed Barcelona, Unitat Rec Neoplasies Hematol, Barcelona, Spain

[3] Hosp del Mar, IMAS, Dept Patol, Lab Citogenet & Biol Mol, Barcelona, Spain

[4] Hosp del Mar, IMAS, Serv Hematol Clin, Barcelona, Spain

来源：

LEUKEMIA | 2006年 / 20卷 / 10期

关键词：

D O I：

10.1038/sj.leu.2404341

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1903 / 1905

页数：4

共 8 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2]

BELLOSILLO B, 2006, LEUKEMIA, V102, P18962

[3] Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study [J].

Campbell, PJ ;

Scott, LM ;

Buck, G ;

Wheatley, K ;

East, CL ;

Marsden, JT ;

Duffy, A ;

Boyd, EM ;

Bench, AJ ;

Scott, MA ;

Vassiliou, GS ;

Milligan, DW ;

Smith, SR ;

Erber, WN ;

Bareford, D ;

Wilkins, BS ;

Reilly, JT ;

Harrison, CN ;

Green, AR .

LANCET, 2005, 366 (9501) :1945-1953

[4]

FLORENSA L, 1995, LEUKEMIA, V9, P271

[5] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[6] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[7] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[8] Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation [J].

Lu, XH ;

Levine, R ;

Tong, W ;

Wernig, G ;

Pikman, Y ;

Zarnegar, S ;

Gilliland, DG ;

Lodish, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (52) :18962-18967

← 1 →